145 research outputs found
Continuous wave optical parametric oscillator for quartz-enhanced photoacoustic trace gas sensing
A continuous wave optical parametric oscillator, generating up to 300 mW idler output in the 3–4 μm wavelength region, and pumped by a fiber-amplified DBR diode laser is used for trace gas detection by means of quartz-enhanced photoacoustic spectroscopy (QEPAS). Mode-hop-free tuning of the OPO output over 5.2 cm-1 and continuous spectral coverage exceeding 16.5 cm-1 were achieved via electronic pump source tuning alone. Online monitoring of the idler wavelength, with feedback to the DBR diode laser, provided an automated closed-loop control allowing arbitrary idler wavelength selection within the pump tuning range and locking of the idler wavelength with a stability of 1.7×10-3 cm-1 over at least 30 min.\ud
\ud
Using this approach, we locked the idler wavelength at an ethane absorption peak and obtained QEPAS data to verify the linear response of the QEPAS signal at different ethane concentrations (100 ppbv-20 ppmv) and different power levels. The detection limit for ethane was determined to be 13 ppbv (20 s averaging), corresponding to a normalized noise equivalent absorption coefficient of 4.4×10-7 cm-1  W/Hz1/2
Retinal thickness as a potential biomarker in patients with amyloid-proven early- and late-onset Alzheimer's disease
Introduction: Retinal thickness measured with optical coherence tomography has been proposed as
a noninvasive biomarker for Alzheimer’s disease (AD). We therefore measured retinal thickness in
well-characterized AD and control participants, considering ophthalmological confounders.
Methods: We included 57 amyloid-proven AD cases and 85 cognitively normal, amyloid-negative
controls. All subjects underwent retinal thickness measurements with spectral domain optical
coherence tomography and an ophthalmological assessment to exclude ocular disease.
Results: Retinal thickness did not discriminate cases from controls, including stratified analyses for
early- versus late-onset AD. We found significant associations between macular thickness and global
cortical atrophy [b 20.358; P 5 .01] and parietal cortical atrophy on magnetic resonance imaging
[b 20.371; P , .01] in AD cases.
Discussion: In this study, representing the largest optical coherence tomography cohort with
amyloid-proven AD cases, we show that retinal thickness does not discriminate AD from controls,
despite evident changes on clinical, neuroimaging, and CSF measures, querying the use of retinal
thickness measurements as an AD biomarke
Retinal and Cerebral Microvasculopathy: Relationships and Their Genetic Contributions
PURPOSE: Retinal microvasculopathy may reflect small vessel disease in the brain. Here we test
the relationships between retinal vascular parameters and small vessel disease, the influence
of cardiovascular risk factors on these relationships, and their common genetic background in
a monozygotic twin cohort.
METHODS: We selected 134 cognitively healthy individuals (67 monozygotic twin pairs) aged
‡60 years from the Netherlands Twin Register for the EMIF-AD PreclinAD study. We measured
seven retinal vascular parameters averaged over both eyes using fundus images analyzed with
Singapore I Vessel Assessment. Small vessel disease was assessed on MRI by a volumetric
measurement of periventricular and deep white matter hyperintensities. We calculated
associations between RVPs and WMH, estimated intratwin pair correlations, and performed
twin-specific analyses on relationships of interest.
RESULTS: Deep white matter hyperintensities volume was positively associated with retinal
tortuosity in veins (P ¼ 0.004) and fractal dimension in arteries (P ¼ 0.001) and veins (P ¼
0.032), periventricular white matter hyperintensities volume was positively associated with
retinal venous width (P ¼ 0.028). Intratwin pair correlations were moderate to high for all
small vessel disease/retinal vascular parameter variables (r ¼ 0.49–0.87, P < 0.001). Crosstwin
cross-trait analyses showed that retinal venous tortuosity of twin 1 could predict deep
white matter hyperintensities volume of the co-twin (r ¼ 0.23, P ¼ 0.030). Within twin-pair
differences for retinal venous tortuosity were associated with within twin-pair differences in
deep white matter hyperintensities volume (r ¼ 0.39, P ¼ 0.001).
CONCLUSIONS: Retinal arterial fractal dimension and venous tortuosity have associations with
deep white matter hyperintensities volume. Twin-specific analyses suggest that retinal venous
tortuosity and deep white matter hyperintensities volume have a common etiology driven by
both shared genetic factors and unique environmental factors, supporting the robustness of
this relationship
Detection of a Single Identical Cytomegalovirus (CMV) Strain in Recently Seroconverted Young Women
Infection with multiple CMV strains is common in immunocompromised hosts, but its occurrence in normal hosts has not been well-studied.We analyzed CMV strains longitudinally in women who acquired CMV while enrolled in a CMV glycoprotein B (gB) vaccine trial. Sequencing of four variable genes was performed in samples collected from seroconversion and up to 34 months thereafter.199 cultured isolates from 53 women and 65 original fluids from a subset of 19 women were sequenced. 51 women were infected with one strain each without evidence for genetic drift; only two women shed multiple strains. Genetic variability among strains increased with the number of sequenced genetic loci. Nevertheless, 13 of 53 women proved to be infected with an identical CMV strain based on sequencing at all four variable genes. CMV vaccine did not alter the degree of genetic diversity amongst strains.Primary CMV infection in healthy women nearly always involves shedding of one strain that remains stable over time. Immunization with CMVgB-1 vaccine strain is not selective against specific strains. Although 75% of women harbored their unique strain, or a strain shared with only one other woman, 25% shared a single common strain, suggesting that this predominant strain with a particular combination of genetic loci is advantageous in this large urban area
Resilience to cognitive impairment in the oldest-old: design of the EMIF-AD 90+ study
BACKGROUND: The oldest-old (subjects aged 90 years and older) population represents the fastest growing segment of society and shows a high dementia prevalence rate of up to 40%. Only a few studies have investigated protective factors for cognitive impairment in the oldest-old. The EMIF-AD 90+ Study aims to identify factors associated with resilience to cognitive impairment in the oldest-old. In this paper we reviewed previous studies on cognitive resilience in the oldest-old and described the design of the EMIF-AD 90+ Study. METHODS: The EMIF-AD 90+ Study aimed to enroll 80 cognitively normal subjects and 40 subjects with cognitive impairment aged 90 years or older. Cognitive impairment was operationalized as amnestic mild cognitive impairment (aMCI), or possible or probable Alzheimer's Disease (AD). The study was part of the European Medical Information Framework for AD (EMIF-AD) and was conducted at the Amsterdam University Medical Centers (UMC) and at the University of Manchester. We will test whether cognitive resilience is associated with cognitive reserve, vascular comorbidities, mood, sleep, sensory system capacity, physical performance and capacity, genetic risk factors, hallmarks of ageing, and markers of neurodegeneration. Markers of neurodegeneration included an amyloid positron emission tomography, amyloid β and tau in cerebrospinal fluid/blood and neurophysiological measures. DISCUSSION: The EMIF-AD 90+ Study will extend our knowledge on resilience to cognitive impairment in the oldest-old by extensive phenotyping of the subjects and the measurement of a wide range of potential protective factors, hallmarks of aging and markers of neurodegeneration. TRIAL REGISTRATION: Nederlands Trial Register NTR5867 . Registered 20 May 2016
The EMIF-AD PreclinAD study: study design and baseline cohort overview
BACKGROUND: Amyloid pathology is the pathological hallmark in Alzheimer’s disease (AD) and can precede clinical
dementia by decades. So far it remains unclear how amyloid pathology leads to cognitive impairment and dementia.
To design AD prevention trials it is key to include cognitively normal subjects at high risk for amyloid pathology and to
find predictors of cognitive decline in these subjects. These goals can be accomplished by targeting twins, with
additional benefits to identify genetic and environmental pathways for amyloid pathology, other AD biomarkers,
and cognitive decline.
METHODS: From December 2014 to October 2017 we enrolled cognitively normal participants aged 60 years and
older from the ongoing Manchester and Newcastle Age and Cognitive Performance Research Cohort and the
Netherlands Twins Register. In Manchester we included single individuals, and in Amsterdam monozygotic twin
pairs. At baseline, participants completed neuropsychological tests and questionnaires, and underwent physical
examination, blood sampling, ultrasound of the carotid arteries, structural and resting state functional brain magnetic
resonance imaging, and dynamic amyloid positron emission tomography (PET) scanning with [18F]flutemetamol. In
addition, the twin cohort underwent lumbar puncture for cerebrospinal fluid collection, buccal cell collection,
magnetoencephalography, optical coherence tomography, and retinal imaging.
RESULTS: We included 285 participants, who were on average 74.8 ± 9.7 years old, 64% female. Fifty-eight participants
(22%) had an abnormal amyloid PET scan.
CONCLUSIONS: A rich baseline dataset of cognitively normal elderly individuals has been established to estimate risk
factors and biomarkers for amyloid pathology and future cognitive declin
Cognitive function and drivers of cognitive impairment in a European and a Korean cohort of people living with HIV
Although cognitive impairments are still prevalent in the current antiretroviral therapy era, limited investigations have compared the prevalence of cognitive disorder in people living with HIV (PLWH) and its determinants in different regions and ethnicities. We compared cognitive performance across six domains using comparable batteries in 134 PLWH aged ≥45 years from the COBRA study (Netherlands, UK), and 194 PLWH aged ≥18 years from the NeuroAIDS Project (South Korea). Cognitive scores were standardized and averaged to obtain domain and global T-scores. Associations with global T-scores were evaluated using multivariable regression and the ability of individual tests to detect cognitive impairment (global T-score ≤45) was assessed using the area-under-the-receiver-operating-characteristic curve (AUROC). The median (interquartile range) age of participants was 56 (51, 62) years in COBRA (88% white ethnicity, 93% male) and 45 (37, 52) years in NeuroAIDS (100% Korean ethnicity, 94% male). The rate of cognitive impairment was 18.8% and 18.0%, respectively (p = 0.86). In COBRA, Black-African ethnicity was the factor most strongly associated with cognitive function (11.1 [7.7, 14.5] lower scores vs. white ethnicity, p < 0.01), whereas in NeuroAIDS, age (0.6 [0.1, 1.3] per 10-year, p<0.01) and education (0.7 [0.5, 0.9] per year, p<0.01) were significantly associated with cognitive function with anemia showing only a weak association (−1.2 [−2.6, 0.3], p=0.12). Cognitive domains most associated with cognitive impairment were attention (AUROC = 0.86) and executive function (AUROC = 0.87) in COBRA and processing speed (AUROC = 0.80), motor function (AUROC = 0.78) and language (AUROC = 0.78) in NeuroAIDS. Two cohorts of PLWH from different geographical regions report similar rates of cognitive impairment but different risk factors and cognitive profiles of impairment
- …